Biocept Stock

Biocept Equity

Delisted

The The Equity of Biocept (BIOC) as of Sep 5, 2026 is 8.86 M USD. In the previous year, The Equity was 37.48 M USD — a change of -76.36% (lower).

Equity

8.86 MUSD

YoY

-76.36%

Last updated:

In 2026, Biocept's equity was 8.86 M USD, a -76.36% increase from the 37.48 M USD equity in the previous year.

The Biocept Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
3.69 M USD
Jan 1, 2016
658,661.00 USD
Jan 1, 2017
1.30 M USD
Jan 1, 2018
3.04 M USD
Jan 1, 2019
11.20 M USD
Jan 1, 2020
23.69 M USD
Jan 1, 2021
37.48 M USD
Jan 1, 2022
8.86 M USD
The Biocept Equity history
YEAREquityYoY
8.86 MUSD-76.36%
37.48 MUSD+58.19%
23.69 MUSD+111.53%
11.20 MUSD+268.14%
3.04 MUSD+134.76%
1.30 MUSD+96.77%
658,661.00USD-82.16%
3.69 MUSD-1,774.19%
-220,569.00USD
Access this data via the Eulerpool API

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Biocept's Equity

Biocept's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biocept's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biocept's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biocept's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biocept’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biocept stock

The Equity of Biocept is 8.86 M USD in 2026.

The Equity of Biocept changed from 37.48 M USD to 8.86 M USD, representing a -76.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Biocept since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Biocept historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Biocept

All Key Metrics — Biocept